The Liver Meeting® 2018
San Francisco, CA.
November 9-13, 2018
Meeting Coverage
SOF/VEL/VOX Successful for Hepatitis C Virus Retreatment in Patients With and Without HIV
Danielle Mroz
Treatment was also successful in patients with prior noncompletion or poor adherence to direct-acting antiviral therapy.
A fixed-dose combination therapy of sofosbuvir, velpatasvir, and voxilaprevir (SOF/VEL/VOX, Vosevi, Gilead) was highly effective after 12 weeks in retreating direct-acting antiviral-experienced patients with hepatitis C virus infection, with and without HIV co-infection, including those with prior noncompletion of treatment or poor adherence, according to results of a new study.
Read More: https://www.mdmag.com/conference-coverage/aasld-2018/sofvelvox-successful-for-hepatitis-c-virus-retreatment-in-patients-with-and-without-hiv
Read More: https://www.mdmag.com/conference-coverage/aasld-2018/sofvelvox-successful-for-hepatitis-c-virus-retreatment-in-patients-with-and-without-hiv
Meeting Updates
No comments:
Post a Comment